Patricia Whitcomb
About
Patricia Whitcomb is a scholar working on Neurology, Epidemiology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Patricia Whitcomb has authored 21 papers receiving a total of 797 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Neurology, 9 papers in Epidemiology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Patricia Whitcomb's work include Neurofibromatosis and Schwannoma Cases (10 papers), Neuroblastoma Research and Treatments (7 papers) and Neuroendocrine Tumor Research Advances (5 papers). Patricia Whitcomb is often cited by papers focused on Neurofibromatosis and Schwannoma Cases (10 papers), Neuroblastoma Research and Treatments (7 papers) and Neuroendocrine Tumor Research Advances (5 papers). Patricia Whitcomb collaborates with scholars based in United States, Malaysia and Canada. Patricia Whitcomb's co-authors include Brigitte C. Widemann, Elizabeth Fox, Frank M. Balis, Eva Dombi, Philip A. Pizzo, Alberta Aikin, Thomas J. Walsh, Sanjay G. Revankar, Maya Lodish and Seth M. Steinberg and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and JNCI Journal of the National Cancer Institute.
In The Last Decade
Patricia Whitcomb
21 papers receiving 777 citations
Peers
Patricia Whitcomb
Qing Wei China
Ioanna Delladetsima Greece
Tzyy‐Choou Wu United States
Liliane Marot Belgium
Serena Formica Italy
Ernest W. Larkin United States
Balan Louis Gaspar India
Amalia Anastasopoulou Greece
Byonggu An Japan
RE Gress United States
Citations per year, relative to Patricia Whitcomb Patricia Whitcomb (= 1×)
peers
Qing Wei
Countries citing papers authored by Patricia Whitcomb
Since
Specialization
Citations
This map shows the geographic impact of Patricia Whitcomb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia Whitcomb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia Whitcomb more than expected).
Fields of papers citing papers by Patricia Whitcomb
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Patricia Whitcomb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia Whitcomb. The network helps show where Patricia Whitcomb may publish in the future.
Co-authorship network of co-authors of Patricia Whitcomb
This figure shows the co-authorship network connecting the top 25 collaborators of Patricia Whitcomb. A scholar is included among the top collaborators of Patricia Whitcomb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia Whitcomb. Patricia Whitcomb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gross, Andrea M., Eva Dombi, Kelly King, et al.. (2022). Audiometric and Otologic Findings in Children and Young Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas. The Laryngoscope. 133(10). 2770–2778.
2.
Jackson, Sadhana, Eva H. Baker, Andrea M. Gross, et al.. (2020). The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. Neuro-Oncology Advances. 2(1). vdaa095–vdaa095.
3.
Coyne, Geraldine O’Sullivan, Andrea M. Gross, Eva Dombi, et al.. (2020). Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. Journal of Clinical Oncology. 38(15_suppl). 3612–3612.
4.
Dombi, Eva, Jared S. Rosenblum, Markku Miettinen, et al.. (2019). Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1. Journal of neurosurgery. 133(5). 1516–1526.
5.
Gross, Andrea M., Pamela L. Wolters, Andrea Baldwin, et al.. (2018). SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. Journal of Clinical Oncology. 36(15_suppl). 10503–10503.
6.
Gross, Andrea M., Pamela L. Wolters, Andrea Baldwin, et al.. (2018). NFM-07. SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN). Neuro-Oncology. 20(suppl_2). i143–i144.
7.
Grohar, Patrick J., John Glod, Cody J. Peer, et al.. (2017). A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS–FLI1 fusion transcript. Cancer Chemotherapy and Pharmacology. 80(3). 645–652.
8.
Bradford, Diana, Patricia Whitcomb, Eva Dombi, et al.. (2016). Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).. Journal of Clinical Oncology. 34(15_suppl). TPS2596–TPS2596.
9.
Nella, Aikaterini A., Maya Lodish, Elizabeth Fox, et al.. (2014). Vandetanib Successfully Controls Medullary Thyroid Cancer-Related Cushing Syndrome in an Adolescent Patient. The Journal of Clinical Endocrinology & Metabolism. 99(9). 3055–3059.
10.
Widemann, Brigitte C., Leigh Marcus, Michael J. Fisher, et al.. (2014). Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).. Journal of Clinical Oncology. 32(15_suppl). 10018–10018.
11.
Fox, Elizabeth, Brigitte C. Widemann, Meredith K. Chuk, et al.. (2013). Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma. Clinical Cancer Research. 19(15). 4239–4248.
12.
Lodish, Maya, Clara C. Chen, Ninet Sinaii, et al.. (2011). 111In-Octreotide Scintigraphy for Identification of Metastatic Medullary Thyroid Carcinoma in Children and Adolescents. The Journal of Clinical Endocrinology & Metabolism. 97(2). E207–E212.
13.
Herzog, Cynthia E., Tanya Trippett, Joseph F. Grippo, et al.. (2010). Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid Tumors. Clinical Cancer Research. 17(3). 611–619.
14.
Meany, Holly J., Frank M. Balis, Alberta Aikin, et al.. (2010). Pediatric Phase I Trial Design Using Maximum Target Inhibition as the Primary Endpoint. JNCI Journal of the National Cancer Institute. 102(12). 909–912.
15.
Fox, Elizabeth, Patricia Whitcomb, Alberta Aikin, et al.. (2009). Phase I/II trial of vandetanib in children and adolescents with hereditary medullary thyroid carcinoma. Journal of Clinical Oncology. 27(15_suppl). 10014–10014.
16.
Bernardi, Ronald J., Lisa Bomgaars, Elizabeth Fox, et al.. (2007). Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemotherapy and Pharmacology. 62(2). 355–361.
17.
Widemann, Brigitte C., Wanda L. Salzer, R.J. Arceci, et al.. (2006). Phase I Trial and Pharmacokinetic Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas. Journal of Clinical Oncology. 24(3). 507–516.
18.
Walsh, Thomas J., Vijay Yeldandi, Maureen McEvoy, et al.. (1998). Safety, Tolerance, and Pharmacokinetics of a Small Unilamellar Liposomal Formulation of Amphotericin B (AmBisome) in Neutropenic Patients. Antimicrobial Agents and Chemotherapy. 42(9). 2391–2398.
19.
Walsh, Thomas J., William G. Merz, James W. Lee, et al.. (1995). Diagnosis and therapeutic monitoring of invasive candidiasis by rapid enzymatic detection of serum d-arabinitol. The American Journal of Medicine. 99(2). 164–172.
20.
Walsh, Thomas J., Patricia Whitcomb, Sanjay G. Revankar, & Philip A. Pizzo. (1995). Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer. 76(11). 2357–2362.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Qing Wei Breakdown of academic impact, for papers by Ioanna Delladetsima Breakdown of academic impact, for papers by Tzyy‐Choou Wu Breakdown of academic impact, for papers by Liliane Marot Breakdown of academic impact, for papers by Serena Formica Breakdown of academic impact, for papers by Ernest W. Larkin Breakdown of academic impact, for papers by Balan Louis Gaspar Breakdown of academic impact, for papers by Amalia Anastasopoulou Breakdown of academic impact, for papers by Byonggu An Breakdown of academic impact, for papers by RE Gress